AKT1 and ovarian carcinoma: Mechanistically, they promote dephosphorylation of the overactivated phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway, reverse cisplatin resistance in ovarian cancer, and exert antitumor effects.